Apollo Hospitals faces 30 percent drug cap: Apollo Hospitals stock has INR 1.1 trillion value

Published on 10/19/2026 at 09:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The oncology drug margin cap takes effect at 30 percent on November 9, 2026. Apollo Hospitals stock has INR 1.1 trillion value on October 19, 2026.

Drug pricing and earnings dates

The oncology drug margin cap takes effect on November 9, 2026 at 30 percent.
Apollo Hospitals reported INR 70.44 billion in Q1 FY27 revenue on August 12, 2026.
Apollo Hospitals had an INR 1.1 trillion market capitalization as of October 19, 2026.

Apollo Hospitals, INE437A01024, Illustration mit AI erstellt.

Apollo Hospitals (ISIN INE437A01024) faces a regulatory margin cap on non-scheduled oncology drugs, while its market capitalization stood at INR 1.1 trillion on October 19, 2026. CNBC TV18 reported that the 30 percent cap will apply from November 9, 2026, with analysts expecting pressure on hospital pharmacy margins.

Regulation puts pharmacy margins first

The policy covers 138 non-scheduled oncology drugs, including high-value molecules such as Bevacizumab. CNBC TV18 reported that hospitals may need to absorb part of the squeeze, while price increases in other areas could offset some of the effect.

The same report cited a 1 percent to 2 percent potential impact for several hospital operators. Apollo Hospitals was included among the companies likely to face near-term pressure, giving the regulatory change a direct earnings relevance.

What does the next quarter add?

Apollo Hospitals reported INR 70.44 billion of revenue in the first quarter of fiscal year 2027, up 21.00 percent year on year, according to The Economic Times on August 12, 2026. That growth provides a quantified operating base against which the drug-margin risk will be assessed.

Three dated milestones shape the story

On May 21, 2026, Apollo Hospitals reported fiscal year 2026 net profit of INR 19.42 billion, according to The Economic Times. On August 12, 2026, first-quarter fiscal year 2027 revenue reached INR 70.44 billion, up 21.00 percent year on year. On October 15, 2026, the company scheduled a conference call for November 5, 2026, to discuss results for the quarter ended September 30, 2026, as reported by StockFin.

Dates investors can mark

The next scheduled company event is the November 5, 2026 conference call on second-quarter fiscal year 2027 results. The underlying reporting period ends September 30, 2026, and management is expected to address the effect of the oncology pricing rules alongside operating performance.

Stock valuation in context

Apollo Hospitals was quoted at INR 7,739.50 on the NSE on October 19, 2026 at 1:02 p.m. IST. Its 52-week range was INR 6,696.50 to INR 9,070.50, placing the latest quote between the two established market levels.

The company is listed on the NSE and BSE and operates in healthcare services. The combination of 21.00 percent first-quarter revenue growth and a possible 1 percent to 2 percent near-term margin effect leaves the November results call as the next quantified test.